NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $4.11 -0.04 (-0.96%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$4.11 0.00 (-0.07%) As of 09/18/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ARS Pharmaceuticals Stock (NASDAQ:SPRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$4.10▼$4.2050-Day Range$4.11▼$7.7452-Week Range$4.10▼$13.15Volume1.89 million shsAverage Volume1.44 million shsMarket Capitalization$408.74 millionP/E RatioN/ADividend YieldN/APrice Target$26.40Consensus RatingModerate Buy Company Overview ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions. The company’s lead product is neffy, an epinephrine nasal spray designed to provide emergency treatment for allergic reactions, including anaphylaxis, without requiring an injection. The U.S. Food and Drug Administration approved neffy in 2024 for adults and children who weigh at least 30 kilograms. The product is intended for use when epinephrine is needed and is designed to address barriers associated with injectable epinephrine, such as needle fear, difficulty with administration, and hesitation to use an auto-injector. ARS Pharmaceuticals was founded in 2015 and is headquartered in San Mateo, California. The company’s operations are primarily focused on advancing and commercializing its epinephrine nasal spray platform and expanding access to emergency allergy treatment in the United States and other markets where the product receives regulatory authorization. Richard Low serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More ARS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreSPRY MarketRank™: ARS Pharmaceuticals scored higher than 34% of companies evaluated by MarketBeat, and ranked 712th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingARS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialARS Pharmaceuticals has a consensus price target of $26.40, representing about 542.3% upside from its current price of $4.11.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($1.90) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.25% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 14.14, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently increased by 1.12%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.05 News SentimentARS Pharmaceuticals has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 16 news articles for ARS Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for SPRY on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders33.80% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRY Stock News HeadlinesARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRYSeptember 18 at 8:32 PM | globenewswire.comSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawSeptember 18 at 9:23 AM | globenewswire.comA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the political and investment landscape. Whitney Tilson believes tensions may come to a head at midnight on November 4th, the day after the midterm elections, with major implications for your portfolio. | Stansberry Research (Ad)Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor HarmSeptember 17 at 12:00 PM | globenewswire.comSPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallStSeptember 17 at 10:07 AM | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRYSeptember 17 at 10:00 AM | prnewswire.comSPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 16, 2026 | prnewswire.comSPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action DeadlineSeptember 16, 2026 | prnewswire.comSee More Headlines SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $11.65 at the beginning of the year. Since then, SPRY shares have decreased by 64.7% and is now trading at $4.11. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) released its quarterly earnings data on Thursday, August, 13th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.15. The firm had revenue of $33.66 million for the quarter, compared to analyst estimates of $31.32 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 256.67% and a negative net margin of 184.24%. Read the conference call transcript. When did ARS Pharmaceuticals IPO? ARS Pharmaceuticals (SPRY) raised $207 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 11,500,000 shares at $17.00-$19.00 per share. Who are ARS Pharmaceuticals' major shareholders? ARS Pharmaceuticals' top institutional shareholders include BlackRock Inc. (5.35%), Tejara Capital Ltd (0.61%), ADAR1 Capital Management LLC (0.61%) and Bank of America Corp DE (0.47%). Insiders that own company stock include Ra Capital Management, LP, Sarina Tanimoto, Richard E Lowenthal, Laura Shawver, Alexander A Fitzpatrick, Eric Karas, Brian Dorsey, Kathleen D Scott, Peter A Thompson, Justin Chakma and Brent L Saunders. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/13/2026Today9/20/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SPRY's financial health is in the Red zone, according to TradeSmith. SPRY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SPRY CIK1671858 Webars-pharma.com Phone(858) 771-9307FaxN/AEmployees200Year Founded2015Price Target and Rating Average Price Target for ARS Pharmaceuticals$26.40 High Price Target$32.00 Low Price Target$15.00 Potential Upside/Downside+542.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$171.30 million Net Margins-184.24% Pretax Margin-184.31% Return on Equity-256.67% Return on Assets-69.63% Debt Debt-to-Equity Ratio13.72 Current Ratio3.48 Quick Ratio3.28 Sales & Book Value Annual Sales$84.28 million Price / Sales4.85 Cash FlowN/A Price / Cash FlowN/A Book Value$1.16 per share Price / Book3.54Miscellaneous Outstanding Shares99,450,000Free Float65,834,000Market Cap$408.74 million OptionableOptionable Beta1.05 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:SPRY) was last updated on 9/20/2026 by MarketBeat.com Staff. From Our Partners“Elon’s nightmare” could fund your retirementMarc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredYou’ve never seen anything like this beforeFor centuries, families like the Rothschilds, Morgans, and Rockefellers have quietly used one overlooked type ...Porter & Company | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredNVDA CEO says it’s a "once-in-a-generation opportunity"NVIDIA CEO Jensen Huang calls a little-known AI niche a once-in-a-generation opportunity, and it has nothing t...Monument Traders Alliance | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
